Title

Partial vena cava occlusion (VCO) to counteract refractory heart failure: A new era in interventional heart failure strategy.

Authors

Yasar Sattar, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital, Queens, NY, USA
Monil Majmundar, New York Medical College, Metropolitan Hospital Center, New York, NY, USA
Talal Almas, Royal College of Surgeons in Ireland, Dublin, Ireland
David Song, Icahn School of Medicine at Mount Sinai, Elmhurst Hospital, Queens, NY, USA
Waqas Ullah, Abington Jefferson Health, Abington, PA, USAFollow
Homam Moussa Pacha, The University of Pittsburgh Medical Center, PA, USA
Mohamed Zghouzi, Detroit Medical Center, Detroit, MI, USA
Islam Y Elgendy, Division of Cardiology, Weill Cornell Medicine-Qatar, Doha, Qatar
Fatir Murtaza, Gomel State Medical University, Gomel, Belarus
M Chadi Alraies, Detroit Medical Center, Detroit, MI, USA

Document Type

Article

Publication Date

5-12-2021

Comments

This article is the author's final published version in Annals of Medicine and Surgery, Volume 66, May 2021, Article number 102387.

The published version is available at https://doi.org/10.1016/j.amsu.2021.102387.

Copyright © 2021 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Abstract

Background: Patients with acute decompensated heart failure are prone to recurrent exacerbation leading to poor quality of life when they do not respond to an optimal medical regimen. Due to the lack of linear positive inotropy response to increasing preload in heart failure patients, increasing preload is associated with poor outcomes. Partial occlusion of either IVC or SVC is a proposed novel treatment that can improve cardiac function or quality of life by altering preload/pressure in heart failure (HF) patients unresponsive to diuretics.

Methods: PubMed, Ovid (MEDLINE), and Cochrane database we searched using the MeSH terms including "Superior vena cava occlusion," "Inferior vena cava occlusion," "Heart failure exacerbation." The inclusion criteria included studies that enrolled patients > 18 years with diagnosed NYHA II-IV HF with reduced ejection fraction (HFrEF) on optimal medical treatment (OMT).

Results: The analysis involved two studies with 14 patients; the mean age was 64.4 ± 10 and 100% males. The difference in the mean pulmonary pressures between pre-and-post VCO devices were 1.56 (95% CI 0.66-2.46, p-value = 0.006). There was no heterogeneity among the study of mean pulmonary pressures. With the use of VC occlusion devices, the mean difference in pulmonary artery systolic pressure decreased by 1.70 (95% CI 0.68-2.71, p-value = 0.001) (Fig. 1B). The heterogeneity of mean pressure was minimal 14%.

Conclusion: In conclusion, VCO can help decrease pulmonary pressure that can indirectly prevent heart failure exacerbations and possibly hospitalization in this cohort of patients.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Recommended Citation

Sattar, Yasar; Majmundar, Monil; Almas, Talal; Song, David; Ullah, Waqas; Pacha, Homam Moussa; Zghouzi, Mohamed; Elgendy, Islam Y; Murtaza, Fatir; and Alraies, M Chadi, "Partial vena cava occlusion (VCO) to counteract refractory heart failure: A new era in interventional heart failure strategy." (2021). Abington Jefferson Health Papers. Paper 60.
https://jdc.jefferson.edu/abingtonfp/60

PubMed ID

34040772

Language

English